Skip to content
Menu

Boston Scientific Corporation BSX

Full chart Compare
Set alert

Price alert · BSX

All alert types
41.98 USD -1.01 (-2.35%)

Regular-session close

42.20 +0.22 +0.52%

After hours · Nov 20, 7:52 PM ET

41.92 Day range 43.22
41.58 52-week range 101.58
YTD
-55.97%
1 year
-56.54%

5D -2.71 (-6.05%)

424344MonTueWedThuFri42.05
Market cap
60.85B
Revenue (ttm)
21.07B
Profit margin
16.62%
EPS (ttm)
2.37
Shares out
1.45B
P/E ratio
17.71
Forward P/E
13.43
YTD return
-55.97%
1-year return
-56.54%
50-day average
43.86
Volume
15.23M
Avg volume
19.51M
Open
42.77
Previous close
42.99
Day's range
41.92 – 43.22
52-week range
41.58 – 101.58
Beta
0.58
Analysts
Buy
Price target
49.60 (+18.1%)
Earnings date
Feb 3, 2027

Key statistics

200-day average
53.25
Enterprise value
73.90B
PEG ratio
0.73
Price / sales
2.89
Price / book
2.38
Revenue growth
1.40%
Free cash flow
2.49B
Total cash
609.00M
Total debt
11.95B
Return on equity
14.12%
Short % of float
2.43%

Fundamental scorecard

17 of 25 checks passed on BSX’s reported financials

ValueGrowthProfitabilityHealthDividend

17of 25 checks passed

  • Value 5 of 5
  • Growth 5 of 5
  • Profitability 4 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
BSX Revenue — quarterly 5.14B
BSX Net income — quarterly 582.00M
BSX EPS — quarterly 0.40

Earnings

BSX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 3, 2027Dec 30, 20260.78———
Oct 28, 2026Sep 30, 20260.7270.730.00+0.41%
Jul 29, 2026Jun 30, 20260.8350.86+0.03+2.99%
Apr 22, 2026Mar 31, 20260.7880.80+0.01+1.52%
Feb 4, 2026Dec 31, 20250.7810.80+0.02+2.43%
Oct 22, 2025Sep 30, 20250.7140.75+0.04+5.04%

Upgrades / downgrades

BSX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 30, 2026TD CowendownBuyHold
Oct 30, 2026BarclaysmainEqual-WeightEqual-Weight
Oct 29, 2026JefferiesdownBuyHold
Oct 29, 2026Canaccord GenuitymainBuyBuy
Oct 29, 2026BernsteinmainOutperformOutperform
Oct 29, 2026RBC CapitalmainOutperformOutperform

About Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on BSX — it syncs with the Stock Master app.

Insider holders

BSX insider holders
InsiderRelationLatest transactionDateShares held
BRENNAN DANIEL JChief Financial OfficerSaleFeb 18, 2025225,808
BROWN VANCE RGeneral CounselConversion of Exercise of derivative securityFeb 12, 202654,244
BUTCHER ARTHUR COfficerConversion of Exercise of derivative securityApr 30, 202677,115
CARRUTHERS WENDYOfficerSaleDec 1, 202429,308
FITZGERALD JOSEPH MICHAELOfficerConversion of Exercise of derivative securityFeb 12, 2026219,141
LUDWIG EDWARD J.DirectorPurchaseJul 30, 202630,359

Institution ownership

BSX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.66%125,556,1195.28BSep 29, 2026
Vanguard Capital Management LLC6.55%94,909,0063.99BSep 29, 2026
State Street Corporation4.64%67,322,5162.83BSep 29, 2026
Primecap Management Company4.04%58,624,9972.47BSep 29, 2026
Vanguard Portfolio Management LLC3.13%45,388,3811.91BSep 29, 2026
Massachusetts Financial Services Co.2.97%43,054,3931.81BSep 29, 2026

Fund ownership

BSX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.26%47,181,2841.98BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.66%38,518,7881.62BJun 29, 2026
VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund2.13%30,831,0391.30BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%19,310,588812.01MSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%18,834,144791.98MSep 29, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.23%17,894,864752.48MSep 29, 2026